Versartis, Inc. is a biotechnology company developing therapeutics for the treatment of endocrine disorders. The company's lead product candidate is VRS-317, a once monthly form of human growth hormone. Versartis is pursuing the development of new therapeutic proteins utilizing the proprietary Amunix half-life extension XTEN technology. XTEN is a novel hydrophilic sequence of natural amino acids and is expressed as a fusion protein with a therapeutically active peptide or protein. New compounds developed by Versartis using the XTEN technology are expected to provide improved therapeutic outcomes such as enhanced efficacy/compliance, fewer side effects, prolonged half-life (up to monthly dosing), as well as low-cost production and enhanced stability.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/15/13 | $25,000,000 | Series C |
Advent Venture Partner Aisling Capital Index Ventures New Leaf Venture Partners | undisclosed |
| 02/18/14 | $55,000,000 | Series E |
Advent Life Sciences Aisling Capital New Leaf Venture Partners Sofinnova Ventures | undisclosed |
